Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Tau promotes neurodegeneration through global chromatin relaxation.

Frost B, Hemberg M, Lewis J, Feany MB.

Nat Neurosci. 2014 Mar;17(3):357-66. doi: 10.1038/nn.3639. Epub 2014 Jan 26.

2.

Targeted Downregulation of dMyc Suppresses Pathogenesis of Human Neuronal Tauopathies in Drosophila by Limiting Heterochromatin Relaxation and Tau Hyperphosphorylation.

Chanu SI, Sarkar S.

Mol Neurobiol. 2017 May;54(4):2706-2719. doi: 10.1007/s12035-016-9858-6. Epub 2016 Mar 21.

PMID:
27000837
3.

Transgenic Drosophila models of Alzheimer's disease and tauopathies.

Iijima-Ando K, Iijima K.

Brain Struct Funct. 2010 Mar;214(2-3):245-62. doi: 10.1007/s00429-009-0234-4. Epub 2009 Dec 5. Review.

4.

Lamin Dysfunction Mediates Neurodegeneration in Tauopathies.

Frost B, Bardai FH, Feany MB.

Curr Biol. 2016 Jan 11;26(1):129-36. doi: 10.1016/j.cub.2015.11.039. Epub 2015 Dec 24.

5.

Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.

Hannan SB, Dräger NM, Rasse TM, Voigt A, Jahn TR.

J Neurochem. 2016 Apr;137(1):12-25. doi: 10.1111/jnc.13532. Epub 2016 Feb 11. Review.

6.

Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies.

Falzone TL, Gunawardena S, McCleary D, Reis GF, Goldstein LS.

Hum Mol Genet. 2010 Nov 15;19(22):4399-408. doi: 10.1093/hmg/ddq363. Epub 2010 Sep 3.

7.
8.

Tau-mediated neurodegeneration in Alzheimer's disease and related disorders.

Ballatore C, Lee VM, Trojanowski JQ.

Nat Rev Neurosci. 2007 Sep;8(9):663-72. Review.

PMID:
17684513
9.

Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.

Brandt R, Hundelt M, Shahani N.

Biochim Biophys Acta. 2005 Jan 3;1739(2-3):331-54. Review.

10.

Neurodegeneration and Alzheimer's disease: the lesson from tauopathies.

Sorrentino G, Bonavita V.

Neurol Sci. 2007 Apr;28(2):63-71. Review.

PMID:
17464468
11.

Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.

Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg GD.

Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9980-5. Epub 2003 Jul 18.

12.

Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration.

Kulic L, Wollmer MA, Rhein V, Pagani L, Kuehnle K, Cattepoel S, Tracy J, Eckert A, Nitsch RM.

Neurobiol Aging. 2011 Oct;32(10):1827-38. doi: 10.1016/j.neurobiolaging.2009.10.014. Epub 2009 Nov 25.

PMID:
19942317
13.

Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.

Vega IE, Cui L, Propst JA, Hutton ML, Lee G, Yen SH.

Brain Res Mol Brain Res. 2005 Aug 18;138(2):135-44.

14.

Tau phosphorylation and aggregation as a therapeutic target in tauopathies.

Badiola N, Suárez-Calvet M, Lleó A.

CNS Neurol Disord Drug Targets. 2010 Dec;9(6):727-40. Review.

PMID:
20942789
15.

Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies.

Higuchi M, Zhang B, Forman MS, Yoshiyama Y, Trojanowski JQ, Lee VM.

J Neurosci. 2005 Oct 12;25(41):9434-43.

16.

Transgenic animal models of tauopathies.

Lee VM, Kenyon TK, Trojanowski JQ.

Biochim Biophys Acta. 2005 Jan 3;1739(2-3):251-9. Review.

17.

Amphiphysin-1 protein level changes associated with tau-mediated neurodegeneration.

De Jesús-Cortés HJ, Nogueras-Ortiz CJ, Gearing M, Arnold SE, Vega IE.

Neuroreport. 2012 Nov 14;23(16):942-6. doi: 10.1097/WNR.0b013e32835982ce.

18.

Propagation of tau pathology in a model of early Alzheimer's disease.

de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT.

Neuron. 2012 Feb 23;73(4):685-97. doi: 10.1016/j.neuron.2011.11.033. Erratum in: Neuron. 2012 Oct 18;76(2):461.

19.

Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies.

Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VM, Trojanowski JQ.

Brain. 2012 Mar;135(Pt 3):807-18. doi: 10.1093/brain/aws013.

20.

Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.

Barten DM, Fanara P, Andorfer C, Hoque N, Wong PY, Husted KH, Cadelina GW, Decarr LB, Yang L, Liu V, Fessler C, Protassio J, Riff T, Turner H, Janus CG, Sankaranarayanan S, Polson C, Meredith JE, Gray G, Hanna A, Olson RE, Kim SH, Vite GD, Lee FY, Albright CF.

J Neurosci. 2012 May 23;32(21):7137-45. doi: 10.1523/JNEUROSCI.0188-12.2012.

Supplemental Content

Support Center